Sun Pharma Advanced Research Company (SPARC) is currently trading at Rs. 432.90, up by 21.15 points or 5.14% from its previous closing of Rs. 411.75 on the BSE.
The scrip opened at Rs. 413.05 and has touched a high and low of Rs. 439.00 and Rs. 406.05 respectively. So far 563081 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 439.00 on 04-Mar-2015 and a 52 week low of Rs. 144.10 on 31-Mar-2014.
Last one week high and low of the scrip stood at Rs. 439.00 and Rs. 365.00 respectively. The current market cap of the company is Rs. 9704.88 crore.
The promoters holding in the company stood at 67.13% while Institutions and Non-Institutions held 6.00% and 26.87% respectively.
Sun Pharma Advanced Research Company (SPARC) has received an approval from US Food and Drug Administration (USFDA) for its New Drug Application (NDA) for ELEPSIA XR (Levetiracetam extended-release tablets 1000 mg and 1500 mg).
ELEPSIA XR is indicated for adjunctive therapy in the treatment of partial onset seizures in patients 12 years of age and older with epilepsy. The product will be manufactured by Sun Pharmaceutical Industries at its Halol facility in Gujarat.
Sun Pharma Advanced Research Company (SPARC) is an international pharmaceutical company engaged in research and development of drugs and delivery systems.
Company Name | CMP |
---|---|
Syngene Internation. | 862.65 |
Sagility India | 28.27 |
AGS Transact Tech | 80.34 |
Just Dial | 1072.55 |
Krystal Integrated | 645.35 |
View more.. |